Immunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15-25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trial.
Saved in:
| Title: | Immunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15-25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trial. |
|---|---|
| Authors: | Mardani M; Infectious Diseases Department, Shahid Beheshti Medical University, Tehran, Iran., Darazam IA; Infectious Diseases Department, Shahid Beheshti Medical University, Tehran, Iran., Moini A; Department of Gynecology and Obstetrics, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran., Ebrahimi A; Orchid Pharmed Company, Tehran, Iran. Electronic address: ebrahimi.a@orchidpharmed.com., Mirhassani R; Nivad Pharmed Salamat, Tehran, Iran. Electronic address: R.mirhassani@nivadpharmed.com., Barati S; Medical Department, Orchid Pharmed Company, Tehran, Iran. Electronic address: barati.s@orchidpharmed.com., Shahpari R; Medical Department, Orchid Pharmed Company, Tehran, Iran. Electronic address: shahpari.r@orchidpharmed.com., Modiri G; Orchid Pharmed Company, Tehran, Iran. Electronic address: modiri.g@orchidpharmed.com., Fallah N; Medical Department, Orchid Pharmed Company, Tehran, Iran. Electronic address: fallah.n@orchidpharmed.com., Albooyeh S; Orchid Pharmed Company, Tehran, Iran. Electronic address: albooyeh.s@orchidpharmed.com., Neyshaburinezhad N; Nivad Pharmed Salamat, Tehran, Iran., Karimi-Zarchi M; Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran., Kashanian M; Iran University of Medical Sciences, Tehran, Iran., Sabzvari A; CinnaGen Medical Biotechnology Research Center, Alborz University of Medical Sciences, Karaj, Iran. Electronic address: sabzvari.a@orchidpharmed.com., Kafi H; Medical Department, Orchid Pharmed Company, Tehran, Iran. Electronic address: kafi.h@orchidpharmed.com. |
| Source: | Vaccine [Vaccine] 2026 Jul 08; Vol. 88, pp. 128886. Date of Electronic Publication: 2026 Jul 08. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42424856 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Immunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15-25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Mardani+M%22">Mardani M</searchLink>; Infectious Diseases Department, Shahid Beheshti Medical University, Tehran, Iran.<br /><searchLink fieldCode="AU" term="%22Darazam+IA%22">Darazam IA</searchLink>; Infectious Diseases Department, Shahid Beheshti Medical University, Tehran, Iran.<br /><searchLink fieldCode="AU" term="%22Moini+A%22">Moini A</searchLink>; Department of Gynecology and Obstetrics, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran.<br /><searchLink fieldCode="AU" term="%22Ebrahimi+A%22">Ebrahimi A</searchLink>; Orchid Pharmed Company, Tehran, Iran. Electronic address: ebrahimi.a@orchidpharmed.com.<br /><searchLink fieldCode="AU" term="%22Mirhassani+R%22">Mirhassani R</searchLink>; Nivad Pharmed Salamat, Tehran, Iran. Electronic address: R.mirhassani@nivadpharmed.com.<br /><searchLink fieldCode="AU" term="%22Barati+S%22">Barati S</searchLink>; Medical Department, Orchid Pharmed Company, Tehran, Iran. Electronic address: barati.s@orchidpharmed.com.<br /><searchLink fieldCode="AU" term="%22Shahpari+R%22">Shahpari R</searchLink>; Medical Department, Orchid Pharmed Company, Tehran, Iran. Electronic address: shahpari.r@orchidpharmed.com.<br /><searchLink fieldCode="AU" term="%22Modiri+G%22">Modiri G</searchLink>; Orchid Pharmed Company, Tehran, Iran. Electronic address: modiri.g@orchidpharmed.com.<br /><searchLink fieldCode="AU" term="%22Fallah+N%22">Fallah N</searchLink>; Medical Department, Orchid Pharmed Company, Tehran, Iran. Electronic address: fallah.n@orchidpharmed.com.<br /><searchLink fieldCode="AU" term="%22Albooyeh+S%22">Albooyeh S</searchLink>; Orchid Pharmed Company, Tehran, Iran. Electronic address: albooyeh.s@orchidpharmed.com.<br /><searchLink fieldCode="AU" term="%22Neyshaburinezhad+N%22">Neyshaburinezhad N</searchLink>; Nivad Pharmed Salamat, Tehran, Iran.<br /><searchLink fieldCode="AU" term="%22Karimi-Zarchi+M%22">Karimi-Zarchi M</searchLink>; Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.<br /><searchLink fieldCode="AU" term="%22Kashanian+M%22">Kashanian M</searchLink>; Iran University of Medical Sciences, Tehran, Iran.<br /><searchLink fieldCode="AU" term="%22Sabzvari+A%22">Sabzvari A</searchLink>; CinnaGen Medical Biotechnology Research Center, Alborz University of Medical Sciences, Karaj, Iran. Electronic address: sabzvari.a@orchidpharmed.com.<br /><searchLink fieldCode="AU" term="%22Kafi+H%22">Kafi H</searchLink>; Medical Department, Orchid Pharmed Company, Tehran, Iran. Electronic address: kafi.h@orchidpharmed.com. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228406899%22">Vaccine</searchLink> [Vaccine] 2026 Jul 08; Vol. 88, pp. 128886. <i>Date of Electronic Publication: </i>2026 Jul 08. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science%22">Elsevier Science </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8406899 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1873-2518 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220264410X%22">0264410X </searchLink><i>NLM ISO Abbreviation: </i>Vaccine <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42424856 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.vaccine.2026.128886 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 128886 Titles: – TitleFull: Immunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15-25-year-old individuals: a phase III, randomized, double-blind, non-inferiority trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Mardani M – PersonEntity: Name: NameFull: Darazam IA – PersonEntity: Name: NameFull: Moini A – PersonEntity: Name: NameFull: Ebrahimi A – PersonEntity: Name: NameFull: Mirhassani R – PersonEntity: Name: NameFull: Barati S – PersonEntity: Name: NameFull: Shahpari R – PersonEntity: Name: NameFull: Modiri G – PersonEntity: Name: NameFull: Fallah N – PersonEntity: Name: NameFull: Albooyeh S – PersonEntity: Name: NameFull: Neyshaburinezhad N – PersonEntity: Name: NameFull: Karimi-Zarchi M – PersonEntity: Name: NameFull: Kashanian M – PersonEntity: Name: NameFull: Sabzvari A – PersonEntity: Name: NameFull: Kafi H IsPartOfRelationships: – BibEntity: Dates: – D: 08 M: 07 Text: 2026 Jul 08 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1873-2518 Numbering: – Type: volume Value: 88 Titles: – TitleFull: Vaccine Type: main |
| ResultId | 1 |
